We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BELLUS Health Inc | TSX:BLU | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 19.48 | 19.46 | 19.52 | 0 | 01:00:00 |
From May 2022 to May 2024
By Adriano Marchese
Bellus Health Inc.'s Toronto-listed shares doubled Tuesday morning after the company agreed to sell itself to British pharmaceutical and biotechnology giant GSK PLC for $2 billion.
At 10:05 a.m. ET, shares trading in Toronto increased twofold to C$19.38.
Shareholders of the Laval, Quebec-based drug-development company will receive $14.75 a share, more than double Monday's U.S.-listed share price of $7.26.
The deal is expected to close by the third quarter of this year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 18, 2023 10:27 ET (14:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BELLUS Health Chart |
1 Month BELLUS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
